LP-284

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameLP-284
Drug Alias Name(+)N-hydroxy-N(methylacylfulvene)ureaLP-284
ClassificationSmall molecules
Mechanisms of ActionDNA damage-binding protein inhibitors
TargetsDNA damage-binding protein
Therapy Area/IndicationsSolid tumoursLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLantern Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesLantern Pharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, Mantle-CellLymphoma, Large B-Cell, Diffuse +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A